Journal Home
Search for

Volume 60, Issue 3, Pages 185-201 (July 2008)


View previous. 2 of 14 View next.

Could transdermal estradiol+progesterone be a safer postmenopausal HRT? A review

Marc L’HermiteaCorresponding Author Informationemail address, Tommaso Simoncinib, Sarah Fullera, Andrea Riccardo Genazzanib

Received 7 March 2008; received in revised form 10 July 2008; accepted 21 July 2008. published online 22 August 2008.

Abstract 

Hormone replacement therapy (HRT) in young postmenopausal women is a safe and effective tool to counteract climacteric symptoms and to prevent long-term degenerative diseases, such as osteoporotic fractures, cardiovascular disease, diabetes mellitus and possibly cognitive impairment. The different types of HRT offer to many extent comparable efficacies on symptoms control; however, the expert selection of specific compounds, doses or routes of administration can provide significant clinical advantages. This paper reviews the role of the non-oral route of administration of sex steroids in the clinical management of postmenopausal women. Non-orally administered estrogens, minimizing the hepatic induction of clotting factors and others proteins associated with the first-pass effect, are associated with potential advantages on the cardiovascular system. In particular, the risk of developing deep vein thrombosis or pulmonary thromboembolism is negligible in comparison to that associated with oral estrogens. In addition, recent indications suggest potential advantages for blood pressure control with non-oral estrogens. To the same extent, a growing literature suggests that the progestins used in association with estrogens may not be equivalent. Recent evidence indeed shows that natural progesterone displays a favorable action on the vessels and on the brain, while this might not be true for some synthetic progestins. Compelling indications also exist that differences might also be present for the risk of developing breast cancer, with recent trials indicating that the association of natural progesterone with estrogens confers less or even no risk of breast cancer as opposed to the use of other synthetic progestins. In conclusion, while all types of hormone replacement therapies are safe and effective and confer significant benefits in the long-term when initiated in young postmenopausal women, in specific clinical settings the choice of the transdermal route of administration of estrogens and the use of natural progesterone might offer significant benefits and added safety.

a Department of Gynecology and Obstetrics, Université Libre de Bruxelles, Bruxelles, Belgium

b Department of Reproductive Medicine and Child Development, Division of Obstetrics and Gynecology, University of Pisa, Pisa, Italy

Corresponding Author InformationCorresponding author at: Service de Gynécologie-Obstétrique, CHU Brugmann, 4 Place Van Gehuchten, B-1020 Bruxelles, Belgium. Tel.: +32 2 477 2534; fax: +32 2 477 2977.

 Parts of this work were presented separately by L’Hermite, Simoncini and Genazzani at the 6th IMS symposium held in Pisa in December 2006; they can be consulted at www.6thimsworkshop.com. The present work has been, however, considerably extended and updated.

PII: S0378-5122(08)00204-1

doi:10.1016/j.maturitas.2008.07.007


View previous. 2 of 14 View next.